FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W482034176> ?p ?o ?g. }

• W482034176 abstract "Endotelyal Progenitor Hucrelerin rhG-CSF Ile Mobilizasyonu Ve Aferezle Toplanan Urundeki Miktari.EPH'lerin eriskin donemde de var oldugunun belirlenmesiyle vaskuler hastaliklarin tedavisinde kullanilmasi gundeme gelmistir. EPH'ler kemik iliginden dolasima katilarak vaskuler hasarin oldugu bolgelerde, hasarin tamir edilmesinde rol almaktadir. EPH'ler kemik iliginden dolasima katildiktan sonra hucre yuzey belirleyicilerinde degisiklik meydana gelmektedir. EPH'lerin CD34-CD133+VEGFR-2+ fenotipinde olanlari en immatur form olarak degerlendirilirken, CD34+CD133+VEGFR-2+ fenotipindeki EPH'ler gercek immatur form olarak degerlendirilmektedir. EPH'ler olgunlasma surecinde bu belirleyicilerden CD133'u kaybederek matur endotel hucrelere (CD34+CD133-VEGFR-2+) donusmektedir.EPH'lerin aferezle toplanmasi ve yarali vaskuler dokuya injeksiyonu ile terapotik etki saglanabilmektedir. Calismamizda EPH'lerin en etkin bicimde kullanilabilmesini saglamak icin aferezle toplanan periferik kok hucre urunun icindeki miktarin belirlenmesini amacladik. Ayrica mobilizasyon oncesi ve sonrasi alinan kan orneklerinde EPH formlarinin dagilimlarini karsilastirarak rhG-CSF'nin artisa olan etkisini belirlemeye calistik.Calismamizda 6 saglikli (5 kadin, 1 erkek) allojeneik kok hucre vericisi dahil edildi. Ortanca yas 36 (28-54) idi. Vericilere mobilizasyon amaciyla 5 gun sure ile 10mcg/kg rhG-CSF uygulandi ve 5. gunde rhG-CSF infuzyonundan 2 saat sonra aferez islemi uygulandi. Vericilerin mobilizasyondan once (bazal), afereze baslamadan once (mobilizasyondan sonra) ve aferez urununden alinan kan orneklerinde CD34-CD133+VEGFR-2+, CD34+CD133+VEGFR-2+ ve CD34+CD133-VEGFR-2+ hucrelerin toplam cekirdekli hucreler icindeki dagilimlari incelendi. Ornekler EDTA'li tuplere alindi ve ayni gun icerisinde akan hucre olcer analizi yapildi.Calismamiz sonucunda 6 saglikli vericiden alinan mobilizasyon oncesi cevresel kanda toplam cekirdekli hucrelerin ortanca %0,0007 (0,0-0,07) sinin EPH (CD34+CD133+VEGFR-2+) oldugunu saptadik. Verici beyaz kure sayisina gore degerlendirdigimizde mikrolitre kanda EPH miktari ortanca 0,005 (0,0-0,44) idi. Mobilizasyon amaciyla rhG-CSF uygulamasini takiben aferez islemi oncesi ve aferez ile toplanan urunde EPH (CD34+CD133+VEGFR-2+) miktarindaki artisin anlamli oldugunu saptadik (p<0,05). En immatur EPH alttipinin (CD34-CD133+VEGFR-2+) rhG-CSF sonrasi bazale gore artisi anlamli degildi. Calismamizda saglikli kisilerde tek basina rhG-CSF uygulamasi sonrasinda ortanca 0,087x106/kg (0,02-0.84) EPH (CD34+CD133+VEGFR-2+) toplanmistir.Sonucta, rhG-CSF EPH miktarini artirirken, EPH'lerde farklilasmaya yol acabilmektedir. Calismamizda elde edilen verilerin ve yontemin vaskulogenezi degerlendiren calismalarin planlanmasina basamak olabilecegini dusunmekteyiz.AbstractThe use of EPCs in the treatment of vascular diseases has been suggested after the invention of the existence of EPCs in adult life. EPCs take place in the repair of the vascular damages after its mobilization from bone marrow to peripheral blood. EPCs are a heterogeneous group of the cells that can be characterized by the expression of surface markers, such as CD34, CD133 and VEGFR-2. Immature stem cells lost CD133 expression during differentiation to mature endothelial cells. EPCs are thought to be a heterogeneous population of progenitors, consisting of real immature CD34+CD133+VEGFR-2+ cells and mature CD34+CD133-VEGFR-2 subtypes. Although CD34+CD133+VEGFR-2+ phenotype represents immature EPCs, the most immature forms of EPCs are CD34-CD133+VEGFR-2+. It has been shown that EPCs might have a role in the repair of injured vascular tissue. The aim of our study was to determine the level of EPCs with in the rhG-CSF mobilized peripheral blood stem cell product. Besides, we try to compare rhG-CSFs effects on the increase of EPC subtypes in samples we have taken before and after mobilization.Six healthy (5 female, 1 male) allogeneic stem cell donors with in median age of 36 years (range 28-54) admitted to our study. Donors received 10µcg/kg rhG-CSF for mobilization of stem cells. On day 5 stem cell collection was performed 2 hours after infusion of rhG-CSF. Blood samples for the analysis of EPCs were obtained prior to rhG-CSF infusion, before stem cell collection and from the stem cell products respectively. Blood samples were taken into tubes with EDTA and the analysis of the EPCs was done on the same day of blood sampling with flow cytometer. We examined CD34-CD133+VEGFR-2+, CD34+CD133+VEGFR-2+ and CD34+CD133-VEGFR-2 cells dispersion in total nucleic cells.In our study we have found that EPCs are 0,0007% (range 0,0-0,007) of the total nucleic cells in blood samples taken prior to rhG-CSF administration. When we made the analysis according to white blood cells count the median count in microliter was 0,005 (range0,0-0,44). We have found that a significant increase in EPC counts occur both in blood samples taken prior to apheresis and from stem cell products (p<0,05). The increase of the most immature EPC subtype (CD34-CD133+VEGFR-2+) after rhG-CSF was not significant in comparison with the basal condition. We collected a median of 0,087x106/kg (range 0,02-0,89) EPCs after rhG-CSF infusion.Briefly, rhG-CSF facilitated the mobilization of EPCs to peripheral blood. Our study showed that G-CSF might lead to differentiation of EPCs as well. In conclusion, obtained data and used method from the study might be first step for planning further studies evaluating the role of EPCs on vasculogenesis." @default.
• W482034176 created "2016-06-24" @default.
• W482034176 creator A5082785244 @default.
• W482034176 date "2010-02-09" @default.
• W482034176 modified "2023-09-27" @default.
• W482034176 title "Endotelyal Progenitor Hücrelerin rhG-CSF İle Mobilizasyonu Ve Aferezle Toplanan Üründeki Miktarı" @default.
• W482034176 hasPublicationYear "2010" @default.
• W482034176 type Work @default.
• W482034176 sameAs 482034176 @default.
• W482034176 citedByCount "0" @default.
• W482034176 crossrefType "dissertation" @default.
• W482034176 hasAuthorship W482034176A5082785244 @default.
• W482034176 hasConcept C101544691 @default.
• W482034176 hasConcept C126322002 @default.
• W482034176 hasConcept C170493617 @default.
• W482034176 hasConcept C19331615 @default.
• W482034176 hasConcept C29456083 @default.
• W482034176 hasConcept C71924100 @default.
• W482034176 hasConceptScore W482034176C101544691 @default.
• W482034176 hasConceptScore W482034176C126322002 @default.
• W482034176 hasConceptScore W482034176C170493617 @default.
• W482034176 hasConceptScore W482034176C19331615 @default.
• W482034176 hasConceptScore W482034176C29456083 @default.
• W482034176 hasConceptScore W482034176C71924100 @default.
• W482034176 hasLocation W4820341761 @default.
• W482034176 hasOpenAccess W482034176 @default.
• W482034176 hasPrimaryLocation W4820341761 @default.
• W482034176 isParatext "false" @default.
• W482034176 isRetracted "false" @default.
• W482034176 magId "482034176" @default.
• W482034176 workType "dissertation" @default.